AstraZeneca

According to Astrazeneca Plc (NASDAQ: AZN) official WeChat message, Andatang (generic name: dapagliflozin) has been approved in the European Union, expanding the indication for the treatment of heart failure with reduced ejection fraction (HFrEF) to cover patients with the entire range of left ventricular ejection fraction (LVEF), including mild and reserved heart failure (HFmrEF, HFpEF).

Japan’s Ministry of Health, Labour and Welfare approved AstraZeneca’s Calquence for the treatment of treatment-naïve adult patients with chronic lymphocytic leukemia (CLL), including small lymphocytic lymphoma (SLL). The approval was supported by data from two trials, including a phase 3 study called ELEVATE-TN.